Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Pharmaceuticals Secures USD $1.9 Million Sales Contract for SmoothX 2% (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > April 29, Next Monday expecting an annual report, will see
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1605)
•••
Comment by Pandoraon Apr 24, 2024 9:03pm
194 Views
Post# 36006271

RE:RE:April 29, Next Monday expecting an annual report, will see

RE:RE:April 29, Next Monday expecting an annual report, will see
riverrrow wrote: Something to look forward to.  GLTA.


 

Theralase 4,167,778-share private placement

 

2024-04-24 20:09 ET - Private Placement

 

The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced on April 24, 2024.

 

Number of shares:  4,167,778 common shares

Purchase price:  18 cents per common share

Warrants:  4,167,778 common share purchase warrants to purchase 4,167,778 common shares

Warrant exercise price:  25 cents per common share for a period of five years

Number of placees:  16 placees

 

The company issued a news release on April 24, 2024, confirming the closing of the private placement.

© 2024 Canjex Publishing Ltd. All rights reserved.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities